The DOI matches its Crossref record; 287 of the 287 references it cites were found in a registry or an index.
Challenges of Antibacterial Discovery
Open accessAbstract
SUMMARY: The discovery of novel small-molecule antibacterial drugs has been stalled for many years. The purpose of this review is to underscore and illustrate those scientific problems unique to the discovery and optimization of novel antibacterial agents that have adversely affected the output of the effort. The major challenges fall into two areas: (i) proper target selection, particularly the necessity of pursuing molecular targets that are not prone to rapid resistance development, and (ii) improvement of chemical libraries to overcome limitations of diversity, especially that which is necessary to overcome barriers to bacterial entry and proclivity to be effluxed, especially in Gram-negative organisms. Failure to address these problems has led to a great deal of misdirected effort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–287 of 287
Urgaonkar, S., Pierre, H. S. L., Meir, I., Lund, H., RayChaudhuri, D., & Shaw, J. T. (2005) · Organic Letters · doi:10.1021/ol052269z · Cited by 92
Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ
Czaplewski, L. G., Collins, I., Boyd, E. A., Brown, D., East, S. P., Gardiner, M., Fletcher, R., Haydon, D. J., Henstock, V., Ingram, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.021 · Cited by 91
Kempsell, K. E., JI, Y.-E., Estrada-G, I. C. E., Colston, M. J., & Cox, R. A. (1992) · Journal of General Microbiology · doi:10.1099/00221287-138-8-1717 · Cited by 91
Structure–activity relationships of ketolides vs. macrolides
Douthwaite, S. R. (2001) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2001.0070s3011.x · Cited by 90
Inhibitors of Pantothenate Kinase: Novel Antibiotics for Staphylococcal Infections
Choudhry, A. E., Mandichak, T., Broskey, J. P., Egolf, R. W., Kinsland, C. L., Begley, T. P., Seefeld, M. A., Ku, T. W., Brown, J. R., Zalacaín, M., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.2051-2055.2003 · Cited by 90
Late stage antibacterial drugs in the clinical pipeline
Projan, S. J., & Bradford, P. A. (2007) · Current Opinion in Microbiology · doi:10.1016/j.mib.2007.08.007 · Cited by 89
Liu, M., Hanks, T. S., Zhang, J., McClure, M. J., Siemsen, D. W., Elser, J. L., Quinn, M. T., & Lei, B. (2006) · Microbiology · doi:10.1099/mic.0.28706-0 · Cited by 89
AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity
Karlowsky, J. A., Kaplan, N., Hafkin, B., Hoban, D. J., & Zhanel, G. G. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00400-09 · Cited by 88
Ohashi, Y., Chijiiwa, Y., Suzuki, K., Takahashi, K., Nanamiya, H., Sato, T., Hosoya, Y., Ochi, K., & Kawamura, F. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.4.1348-1351.1999 · Cited by 87
Yang, Y., Severin, A. I., Chopra, R., Krishnamurthy, G., Singh, G., Hu, W. K., Keeney, D. R., Svenson, K., Petersen, P. J., Labthavikul, P., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.556-564.2006 · Cited by 83
Kurosu, M., Narayanasamy, P., Biswas, K., Dhiman, R. K., & Crick, D. C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070638m · Cited by 82
A mechanistical model for the uptake of sulfonamides by bacteria
Zarfl, C., Matthies, M., & Klasmeier, J. (2007) · Chemosphere · doi:10.1016/j.chemosphere.2007.07.045 · Cited by 81
An Oligomer-Based Approach to Skeletal Diversity in Small-Molecule Synthesis
Spiegel, D. A., Schroeder, F. C., Duvall, J. R., & Schreiber, S. L. (2006) · Journal of the American Chemical Society · doi:10.1021/ja065724a · Cited by 79
Miller, K. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf044 · Cited by 79
Are natural products still the best source for antibacterial discovery? The bacterial entry factor
Silver, L. L. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.5.487 · Cited by 78
Self-citationBacterial proteomics and its role in antibacterial drug discovery
Brötz‐Oesterhelt, H., Bandow, J. E., & Labischinski, H. (2004) · Mass Spectrometry Reviews · doi:10.1002/mas.20030 · Cited by 78
Park, H. S., Yoon, Y. M., Jung, S. J., Kim, C. M., Kim, J. M., & Kwak, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm236 · Cited by 77
Ji, Y., Yin, D., Fox, B. A., Holmes, D. J., Payne, D. J., & Rosenberg, M. (2004) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(03)00931-5 · Cited by 77
Durrant, J. D., Amaro, R. E., Xie, L., Urbaniak, M. D., Ferguson, M. A. J., Haapalainen, A. M., Chen, Z., Guilmi, A. M. D., Wunder, F., Bourne, P. E., et al. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000648 · Cited by 77
Beyer, D., Kroll, H., Endermann, R., Schiffer, G., Siegel, S., Bauser, M., Pohlmann, J., Brands, M., Ziegelbauer, K. B., Haebich, D., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.525-532.2004 · Cited by 76
Robertson, G. T., Bonventre, E. J., Doyle, T. B., Du, Q., Duncan, L. R., Morris, T. W., Roche, E. D., Yan, D., & Lynch, A. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01649-07 · Cited by 76
Biological Activities of Novel Gyrase Inhibitors of the Aminocoumarin Class
Anderle, C., Stieger, M., Burrell, M. R., Reinelt, S., Maxwell, A., Page, M. G. P., & Heide, L. E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01235-07 · Cited by 76
Novel Bacterial Acetyl Coenzyme A Carboxylase Inhibitors with Antibiotic Efficacy In Vivo
Freiberg, C., Pohlmann, J., Nell, P. G., Endermann, R., Schuhmacher, J., Newton, B., Otteneder, M. B., Lampe, T. F. J., Häbich, D., & Ziegelbauer, K. B. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00012-06 · Cited by 75
Quinolone Resistance Due to Reduced Target Enzyme Expression
İnce, D., & Hooper, D. C. (2003) · Journal of Bacteriology · doi:10.1128/jb.185.23.6883-6892.2003 · Cited by 74
Francisco, G. D., Li, Z., Albright, J. D., Eudy, N. H., Katz, A. H., Petersen, P. J., Labthavikul, P., Singh, G., Yang, Y., Rasmussen, B. A., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.082 · Cited by 74
Lipiarmycin, a new antibiotic from Actinoplanes. III. Mechanism of action.
SERGIO, S., PIRALI, G., White, R. J., & PARENTI, F. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.543 · Cited by 73
Platensimycin Activity against Mycobacterial β-Ketoacyl-ACP Synthases
Brown, A. K., Taylor, R. C., Bhatt, A., Fütterer, K., & Besra, G. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006306 · Cited by 73
Identification and Characterization of Inhibitors of Bacterial Enoyl-Acyl Carrier Protein Reductase
Ling, L. L., Xian, J., Ali, S. M. A., Bolin, G., Fan, J., Mills, D. M., Arvanites, A. C., Orgueira, H. A., Ashwell, M. A., Carmel, G., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1541-1547.2004 · Cited by 71
Pan, X.-S., Gould, K. A., & Fisher, L. M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-09 · Cited by 70
The Expanding Role of Lipid II as a Target for Lantibiotics
Martin, N. I., & Breukink, E. J. (2007) · Future Microbiology · doi:10.2217/17460913.2.5.513 · Cited by 69
Discovery of antibacterial cyclic peptides that inhibit the ClpXP protease
Cheng, L. Z., Naumann, T. A., Horswill, A. R., Hong, S., Venters, B. J., Tomsho, J. W., Benkovic, S. J., & Keiler, K. C. (2007) · Protein Science · doi:10.1110/ps.072933007 · Cited by 68
Strahilevitz, J., & Hooper, D. C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1949-1956.2005 · Cited by 67
New Class of Competitive Inhibitor of Bacterial Histidine Kinases
Gilmour, R., Foster, J. E., Sheng, Q., et al. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.23.8196-8200.2005 · Cited by 67
Compensatory Evolution Reveals Functional Interactions between Ribosomal Proteins S12, L14 and L19
Maisnier‐Patin, S., Paulander, W., Pennhag, A. A. L., & Andersson, D. I. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.047 · Cited by 65
Cai, H., Rose, K., Liang, L.-H., Dunham, S. A., & Stover, C. K. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.10.041 · Cited by 65
Bacterial Signal Transduction: Networks and Drug Targets
Utsumi, R. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-78885-2 · Cited by 63
Butler, M. M., LaMarr, W. A., Foster, K. A., Barnes, M. H., Skow, D. J., Lyden, P. T., Kustigian, L. M., Zhi, C., Brown, N. C., Wright, G. E., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01311-05 · Cited by 63
New antibiotic discovery, novel screens, novel targets and impact of microbial genomics
Allsop, A. E. (1998) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(98)80085-4 · Cited by 62
Kitagawa, H., Ozawa, T., Takahata, S., Iida, M., Saito, J., & Yamada, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0705354 · Cited by 61
Leakage of periplasmic enzymes from envA1 strains of Escherichia coli
Young, K., & Silver, L. L. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.12.3609-3614.1991 · Cited by 59
Self-citationZoeiby, A. E., Sanschagrin, F., Darveau, A., Brisson, J.-R., & Lévesque, R. C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg010 · Cited by 56
İnce, D., & Hooper, D. C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3344-3350.2000 · Cited by 53
Lipid II and other bactoprenol-bound cell wall precursors as drug targets.
Schneider, T., & Sahl, H.-G. (2010) · PubMed · Cited by 53
Zeng, B., Wong, K. K., Pompliano, D. L., Reddy, S. G., & Tanner, M. E. (1998) · The Journal of Organic Chemistry · doi:10.1021/jo981895p · Cited by 52
Leeds, J. A., Schmitt, E. K., & Krastel, P. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.211 · Cited by 52
Novel synthetic molecules targeting the bacterial RNA polymerase assembly
André, E., Bastide, L., Michaux‐Charachon, S., Gouby, A., Villain-Guillot, P., Latouche, J., Bouchet‐Spinelli, A., Gualtiéri, M., & Léonetti, J. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki426 · Cited by 52
Wang, W.-L., Chai, S. C., Huang, M., He, H.-Z., Hurley, T. D., & Ye, Q.-Z. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8005788 · Cited by 50
Langsdorf, E. F., Malikzay, A., LaMarr, W. A., Daubaras, D. L., Kravec, C., Zhang, R., Hart, R. F., Monsma, F. J., Black, T. A., Özbal, C. C., et al. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109355319 · Cited by 50
Yuan, Z., & White, R. J. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.015 · Cited by 48
Synthesis and biological evaluation of new glutamic acid-based inhibitors of MurD ligase
Tomašič, T., Zidar, N., Rupnik, V., Kovač, A., Blanot, D., Gobec, S., Kikelj, D., & Mašič, L. P. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.129 · Cited by 48
Structure–activity relationships of novel potent MurF inhibitors
Gu, Y. G., Florjancic, A. S., Clark, R. F., Zhang, T., Cooper, C. S., Anderson, D. D., Lerner, C. G., McCall, J., Cai, Y., Black‐Schaefer, C. L., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.073 · Cited by 48
O'Neill, A. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.297 · Cited by 47
From Vancomycin to Oritavancin: The Discovery and Development of a Novel Lipoglycopeptide Antibiotic
Allen, N. E. (2010) · Anti-Infective Agents · doi:10.2174/187152110790886745 · Cited by 47
Moore, C. B., Oakley, K. L., & Denning, D. W. (2001) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2001.00158.x · Cited by 46
Kamal, Ä., Azeeza, S., Malik, M. S., Shaik, A. A., & Rao, M. V. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j36k5k · Cited by 46
Identification of Antimicrobial Targets Using a Comprehensive Genomic Approach
Yin, D., Fox, B. A., Lonetto, M. L., Etherton, M. R., Payne, D. J., Holmes, D. J., Rosenberg, M. J., & Ji, Y. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.1.101.25679 · Cited by 45
Naphthyl Tetronic Acids as Multi‐Target Inhibitors of Bacterial Peptidoglycan Biosynthesis
Mansour, T. S., Caufield, C. E., Rasmussen, B. A., Chopra, R., Krishnamurthy, G., Morris, K., Svenson, K., Bard, J., Smeltzer, C., Naughton, S., et al. (2007) · ChemMedChem · doi:10.1002/cmdc.200700094 · Cited by 45
MurF Inhibitors with Antibacterial Activity: Effect on Muropeptide Levels
Baum, E. Z., Crespo‐Carbone, S. M., Foleno, B. D., Simon, L. D., Guillemont, J., Macielag, M. J., & Bush, K. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00166-09 · Cited by 45
Brinster, S., Lamberet, G., Staels, B., Trieu‐Cuot, P., Gruss, A., & Poyart, C. (2010) · Nature · doi:10.1038/nature08668 · Cited by 44
Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases
MARSH, B., & Stenzel‐Poore, M. P. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.09.009 · Cited by 43
The Discovery of Cell Wall Active Antibacterial Antibiotics
Gadebusch, H. H., STAPLEY, E. O., & ZIMMERMAN, S. B. (1992) · Critical Reviews in Biotechnology · doi:10.3109/07388559209069193 · Cited by 43
Arhin, F. F., Bélanger, O., Ciblat, S., Dehbi, M., Delorme, D., Dietrich, E., Dixit, D. M., Lafontaine, Y., Lehoux, D. E., Liu, J., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.05.035 · Cited by 41
Li, Z., Francisco, G. D., Hu, W. K., Labthavikul, P., Petersen, P. J., Severin, A. I., Singh, G., Yang, Y., Rasmussen, B. A., Lin, Y., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00471-2 · Cited by 40
A Strategy for the Chemotherapy of Infectious Disease
Cohen, S. S. (1977) · Science · doi:10.1126/science.195340 · Cited by 39
Engineering a Cell-Free Murein Biosynthetic Pathway: Combinatorial Enzymology in Drug Discovery
Wong, K. K., Kuo, D. W., Chabin, R. M., Fournier, C., Gegnas, L. D., Waddell, S. T., Marsilio, F., Leiting, B., & Pompliano, D. L. (1998) · Journal of the American Chemical Society · doi:10.1021/ja983468z · Cited by 38
Whos Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori
Jones, K. R., Cha, J., & Merrell, D. S. (2008) · Current Drug Therapy · doi:10.2174/157488508785747899 · Cited by 36
Low hanging fruit in infectious disease drug development
Kraus, C. N. (2008) · Current Opinion in Microbiology · doi:10.1016/j.mib.2008.09.009 · Cited by 36
Ito, H., Ura, A., Oyamada, Y., Tanitame, A., Yoshida, H., Yamada, S., Wachi, M., & Yamagishi, J. (2006) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2006.tb03851.x · Cited by 36
DeJonge, B. L. M., Kutschke, A., Uria-Nickelsen, M. R., Kamp, H. D., & Mills, S. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00226-09 · Cited by 35
Fatty Acyl Benzamido Antibacterials Based on Inhibition of DnaK-catalyzed Protein Folding
Liebscher, M., Jahreis, G., Lücke, C., Grabley, S., Raina, S., & Schiene‐Fischer, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607667200 · Cited by 34
Two forms of antimicrobial resistance: bacterial persistence and positive function resistance
Bryan, L. E. (1989) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/23.6.817 · Cited by 33
Shin, H., Gennadios, H. A., Whittington, D. A., & Christianson, D. W. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.01.044 · Cited by 33
Recent Advances in the Discovery of Hybrid Antibacterial Agents
Barbachyn, M. R. (2008) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)00017-1 · Cited by 32
Cheng, J., Thanassi, J. A., Thoma, C. L., Bradbury, B. J., Deshpande, M., & Pucci, M. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00158-07 · Cited by 32
Pucci, M. J., Cheng, J., Podos, S. D., Thoma, C. L., Thanassi, J. A., Buechter, D. D., Mushtaq, G., Vigliotti, G. A., Bradbury, B. J., & Deshpande, M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01315-06 · Cited by 30
Bandow, J. E., & Hecker, M. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-7567-6_4 · Cited by 29
Gould, C. V., Sniegowski, P., Shchepetov, M., Metlay, J. P., & Weiser, J. N. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00336-07 · Cited by 28
Active site directed inhibitors of replication-specific bacterial DNA polymerases.
Wright, G., Brown, N., Xu, W.-C., Long, Z.-Y., Zhi, C., Gambino, J., Barnes, M., & Butler, M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.11.016 · Cited by 25
AG205, a Novel Agent Directed against FabK of Streptococcus pneumoniae
Takahata, S., Iida, M., Osaki, Y., Saito, J., Kitagawa, H., Ozawa, T., Yoshida, T., & Hoshiko, S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00270-06 · Cited by 24
Xu, H. H., Real, L. J., & Bailey, M. W. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.166 · Cited by 23
Glycopeptide Resistance in Enterococci
Périchon, B., & Courvalin, P. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-180-2_20 · Cited by 20
Butler, M., Skow, D., Stephenson, R. O., Lyden, P. T., Lamarr, W., & Foster, K. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.12.3770-3775.2002 · Cited by 20
The production of bactericidal fatty acids from glycerides in staphylococcal abscesses
Shryock, T. R., & Kapral, F. A. (1992) · Journal of Medical Microbiology · doi:10.1099/00222615-36-4-288 · Cited by 19
Shen, R., Olcott, M. C., Kim, J., Rajagopal, I., & Mathews, C. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402750200 · Cited by 18
Yao, J., Zhang, Q., Min, J. S., He, J., & Yu, Z. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.042 · Cited by 18
Towards Proteome–Wide Interaction Models Using the Proteochemometrics Approach
Strömbergsson, H., Lapins, M., Kleywegt, G. J., & Wikberg, J. E. S. (2010) · Molecular Informatics · doi:10.1002/minf.201000052 · Cited by 15
Fulmer, T. (2009) · Science-Business eXchange · doi:10.1038/scibx.2009.430 · Cited by 7
Research works printed but not linked: 114
- 10.1016/S1044-0305(96)00104-3 · doi:10.1016/s1044-0305(96)00104-3
- 10.1016/j.bmcl.2007.02.056 · doi:10.1016/j.bmcl.2007.02.056
- 10.1021/jm020483c · doi:10.1021/jm020483c
- 10.1016/S0960-894X(00)00073-1 · doi:10.1016/s0960-894x(00)00073-1
- 10.1016/j.bmcl.2005.09.021 · doi:10.1016/j.bmcl.2005.09.021
- 10.1128/AAC.45.4.1058-1064.2001 · doi:10.1128/aac.45.4.1058-1064.2001
- 10.1155/2010/315056 · doi:10.1155/2010/315056
- Baltz, R. H. 2005. Antibiotic discovery from Actinomycetes: will a renaissance follow the decline and fall. SIM News 55 : 186-196.
- 10.1021/bi900167q · doi:10.1021/bi900167q
- 10.1021/bi6025165 · doi:10.1021/bi6025165
- 10.1128/AAC.46.4.943-946.2002 · DOI
- 10.1128/AAC.50.1.230-236.2006 · doi:10.1128/aac.50.1.230-236.2006
- 10.1128/AAC.00845-07 · doi:10.1128/aac.00845-07
- 10.1111/j.1574-6968.1988.tb13933.x · doi:10.1111/j.1574-6968.1988.tb13933.x
- 10.1016/0006-291X(86)90452-3 · doi:10.1016/0006-291x(86)90452-3
- 10.1021/bi050767 · doi:10.1021/bi050767
- 10.1016/j.coph.2008.04.009 · doi:10.1016/j.coph.2008.04.009
- 10.2174/092986707780831168 · doi:10.2174/092986707780831168
- 10.1016/S0960-894X(02)01076-4 · doi:10.1016/s0960-894x(02)01076-4
- Brown D. W. 2010. The evolution of a fosfomycin resistance enzyme FosA from P. aeruginosa and the development of a high throughput screen for the discovery of bioactive inhibitors. Ph.D. thesis. Vanderbilt University Nashville TN.
- 10.1128/jb.171.7.4071-4072.1989 · doi:10.1128/jb.171.7.4071-4072.1989
- 10.1021/jm800318d · doi:10.1021/jm800318d
- 10.2174/187152109787047805 · doi:10.2174/187152109787047805
- 10.1006/jmbi.1996.0274 · doi:10.1006/jmbi.1996.0274
- 10.1128/AAC.48.1.250-261.2004 · doi:10.1128/aac.48.1.250-261.2004
- Chopra, I. 2000. New drugs for the superbugs. Microbiol. Today 27 : 4-6.
- 10.1021/jm00010a027 · doi:10.1021/jm00010a027
- 10.1517/13543770902766829 · doi:10.1517/13543770902766829
- 10.7164/antibiotics.40.761 · doi:10.7164/antibiotics.40.761
- 10.1021/jm020901d · doi:10.1021/jm020901d
- Drlica, K. 2001. A strategy for fighting antibiotic resistance. ASM News 67 : 27-33.
- 10.1086/499046 · DOI
- 10.1016/j.bmcl.2008.11.102 · doi:10.1016/j.bmcl.2008.11.102
- 10.1016/j.bbapap.2003.11.006 · doi:10.1016/j.bbapap.2003.11.006
- Elespuru, R. K., and R. J. White. 1983. Biochemical prophage induction assay: a rapid test for antitumor agents that interact with DNA. Cancer Res. 43 : 2819-2830.
- 10.1074/jbc.M414412200 · doi:10.1074/jbc.m414412200
- 10.1128/AAC.49.9.3715-3723.2005 · doi:10.1128/aac.49.9.3715-3723.2005
- Evdokimov, A., M. Pokross, R. L. Walter, M. Mekel, B. L. Barnett, J. Amburgey, W. L. Seibel, S. J. Soper, J. F. Djung, N. Fairweather, C. Diven, V. Rastogi, L. Grinius, C. Klanke, R. Siehnel, T. Twinem, R. Andrews, and A. Curnow. 2007. Serendipitous discovery of novel bacterial methionine aminopeptidase inhibitors. Proteins 66 : 538-546. · doi:10.1002/prot.21207
- 10.1128/AAC.50.4.1136-1142.2006 · doi:10.1128/aac.50.4.1136-1142.2006
- 10.1016/S0960-894X(98)00285-6 · doi:10.1016/s0960-894x(98)00285-6
- 10.1016/j.bmcl.2008.11.113 · doi:10.1016/j.bmcl.2008.11.113
- 10.1128/jb.88.4.1112-1118.1964 · doi:10.1128/jb.88.4.1112-1118.1964
- 10.1128/AAC.00275-08 · doi:10.1128/aac.00275-08
- 10.1128/AAC.00596-06 · doi:10.1128/aac.00596-06
- 10.1128/AAC.50.1.401-402.2006 · doi:10.1128/aac.50.1.401-402.2006
- Guay, D. R. 2007. Drug forecast—the peptide deformylase inhibitors as antibacterial agents. Ther. Clin. Risk Manage. 3 : 513-525.
- 10.1128/AAC.49.8.3178-3181.2005 · doi:10.1128/aac.49.8.3178-3181.2005
- 10.1007/BF01709702 · doi:10.1007/bf01709702
- 10.1128/AAC.22.4.662 · doi:10.1128/aac.22.4.662
- 10.1021/jm050920y · doi:10.1021/jm050920y
- 10.1128/AAC.01321-06 · doi:10.1128/aac.01321-06
- 10.1016/S0968-0896(03)00083-X · doi:10.1016/s0968-0896(03)00083-x
- 10.1128/AAC.49.1.131-136.2005 · doi:10.1128/aac.49.1.131-136.2005
- 10.1128/AAC.01254-06 · doi:10.1128/aac.01254-06
- 10.1038/nbt1206-1529 · doi:10.1038/nbt1206-1529
- 10.1001/archinte.1956.00250250007001 · doi:10.1001/archinte.1956.00250250007001
- Kitamoto, O., N. Kasai, K. Fukuya, and A. Kawashima. 1956. Drug sensitivity of the Shigella strains isolated in 1955. J. Jpn. Assoc. Infect. Dis. 30 : 403-404.
- 10.1128/AAC.40.8.1768 · doi:10.1128/aac.40.8.1768
- 10.2174/138161207781368828 · doi:10.2174/138161207781368828
- 10.1128/AAC.49.3.987-995.2005 · DOI
- 10.1016/j.bmcl.2005.03.058 · DOI
- 10.1248/bpb.32.2061 · doi:10.1248/bpb.32.2061
- 10.1021/bi100523c · doi:10.1021/bi100523c
- Leeds, J. A., and C. R. Dean. 2006. Peptide deformylase as an antibacterial target: a critical assessment. Curr. Opin. Pharmacol. 8 : 8.
- 10.1128/AAC.00073-07 · doi:10.1128/aac.00073-07
- 10.1007/BF00341730 · doi:10.1007/bf00341730
- 10.1128/jb.109.1.326-335.1972 · doi:10.1128/jb.109.1.326-335.1972
- 10.1128/jb.110.1.35-40.1972 · doi:10.1128/jb.110.1.35-40.1972
- 10.1128/jb.110.1.41-46.1972 · doi:10.1128/jb.110.1.41-46.1972
- 10.1128/jb.113.1.96-104.1973 · doi:10.1128/jb.113.1.96-104.1973
- 10.1128/AAC.50.4.1228-1237.2006 · doi:10.1128/aac.50.4.1228-1237.2006
- 10.1128/AAC.42.11.2836 · doi:10.1128/aac.42.11.2836
- 10.1128/AAC.18.2.215 · doi:10.1128/aac.18.2.215
- Miller, D. J., S. M. Hammond, D. Anderluzzi, and T. D. Bugg. 1998. Aminoalkylphosphinate inhibitors of d-Ala-d-Ala adding enzyme. J. Chem. Soc. Perkin 1 1 : 131-142.
- Miller, M. 1995. Aminoglycoside transport, p. 175-219. In N. Georgopapdakou (ed.), Drug transport in antimicrobial and anticancer chemotherapy. Marcel Dekker, Inc., New York, NY.
- 10.1021/jm020050 · doi:10.1021/jm020050
- 10.1016/j.bmcl.2004.01.014 · doi:10.1016/j.bmcl.2004.01.014
- 10.1093/jac/dkn261 · doi:10.1093/jac/dkn261
- 10.1016/j.exppara.2007.06.008 · doi:10.1016/j.exppara.2007.06.008
- 10.2174/092986707781368414 · doi:10.2174/092986707781368414
- Oiwa, R. 1992. Antibacterial agents, p. 1-29. In S. Omura (ed.), The search for bioactive compounds from microorganisms. Springer-Verlag, New York, NY.
- 10.1128/AAC.45.1.1599-1600.2001 · doi:10.1128/aac.45.1.1599-1600.2001
- 10.1534/genetics.109.113514 · doi:10.1534/genetics.109.113514
- 10.1016/j.bmcl.2008.02.009 · doi:10.1016/j.bmcl.2008.02.009
- 10.1016/j.bmcl.2008.10.040 · doi:10.1016/j.bmcl.2008.10.040
- 10.1111/j.1465-0691.2004.1006.x · doi:10.1111/j.1465-0691.2004.1006.x
- 10.1128/AAC.48.12.4835-4842.2004 · DOI
- 10.1016/S0960-894X(01)00251-7 · doi:10.1016/s0960-894x(01)00251-7
- 10.1517/17425250902988487 · doi:10.1517/17425250902988487
- Ryder, N. S. 2009. Discontinued drugs in 2008: anti-infectives. Expert Opin. Invest. Drugs 19 : 1-21.
- 10.1093/oxfordjournals.jbchem.a130606 · doi:10.1093/oxfordjournals.jbchem.a130606
- 10.1159/000472864 · doi:10.1159/000472864
- 10.7164/antibiotics.50.22 · doi:10.7164/antibiotics.50.22
- 10.1517/14728220903005590 · doi:10.1517/14728220903005590
- Silver, L. L. 2005. A retrospective on the failures and successes of antibacterial drug discovery. IDrugs 8 : 651-655.
- 10.1016/j.bcp.2005.10.029 · doi:10.1016/j.bcp.2005.10.029
- Skipper, H. E., J. R. Thomson, and M. Bell. 1954. Attempts at dual blocking of biochemical events in cancer chemotherapy. Cancer Res. 14 : 503-507.
- 10.1111/j.1464-410X.1963.tb02604.x · doi:10.1111/j.1464-410x.1963.tb02604.x
- 10.1128/jb.132.1.73-79.1977 · doi:10.1128/jb.132.1.73-79.1977
- 10.1111/j.1747-0285.2005.00317.x · doi:10.1111/j.1747-0285.2005.00317.x
- 10.1128/am.6.6.392-398.1958 · doi:10.1128/am.6.6.392-398.1958
- 10.1016/j.bmcl.2009.07.141 · doi:10.1016/j.bmcl.2009.07.141
- 10.1021/jm030394f · doi:10.1021/jm030394f
- 10.1016/j.bmcl.2005.06.103 · doi:10.1016/j.bmcl.2005.06.103
- 10.1021/jo951780a · doi:10.1021/jo951780a
- Tomasic, T., N. Zidar, A. Kovac, S. Turk, M. Simcic, D. Blanot, M. Müller-Premru, M. Filipic, S. Golic Grdadolnik, A. Zega, M. Anderluh, S. Gobec, D. Kikelj, and L. P. Masic. 2009. 5-Benzylidenethiazolidin-4-ones as multitarget inhibitors of bacterial Mur ligases. ChemMedChem 5 : 286-295.
- 10.1054/drup.1999.0111 · doi:10.1054/drup.1999.0111
- Tung, R. D. 2002. Design and synthesis of amprenavir, a novel HIV protease inhibitor. Infect. Dis. Ther. 25 : 101-118.
- 10.1016/j.bmc.2009.01.052 · doi:10.1016/j.bmc.2009.01.052
- 10.1111/j.1365-2885.1994.tb00251.x · DOI
- 10.7164/antibiotics.56.1045 · doi:10.7164/antibiotics.56.1045
- 10.1016/j.bmcl.2007.03.004 · doi:10.1016/j.bmcl.2007.03.004
- Woodruff, H. B., J. M. Mata, S. Hernàndez, S. Mochales, A. Rodríguez, E. O. Stapley, H. Wallick, A. K. Miller, and D. Hendlin. 1977. Fosfomycin: laboratory studies. Chemotherapy 23 : 1-22.
- 10.1111/j.1749-6632.1974.tb43292.x · doi:10.1111/j.1749-6632.1974.tb43292.x
Cited by
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Antibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
Li, X.-Z., Plésiat, P., & Nikaido, H. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-14 · Cited by 1,614
Metadata
- Authors
- Silver, L. L.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2011-01
- Volume
- 24
- Issue
- 1
- Pages
- 71-109
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2139516496
- Cited by
- 1,376
- References
- 287
- FWCI
- 27.74
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.